TY  - GEN
AU  - Tourani,Jean-Marc
AU  - Pfister,Christian
AU  - Tubiana,Nicole
AU  - Ouldkaci,Mahmoud
AU  - Prevot,Gilles
AU  - Lucas,Virginie
AU  - Oudard,Stéphane
AU  - Malet,Maxime
AU  - Cottu,Paul
AU  - Ferrero,Jean-Marc
AU  - Mayeur,Didier
AU  - Rixe,Olivier
AU  - Sun,Xu-Shan
AU  - Bernard,Olivier
AU  - Andre,Thierry
AU  - Tournigand,Christophe
AU  - Muracciole,Xavier
AU  - Guilhot,Joelle
TI  - Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group
SN  - 0732-183X
PY  - 2003///1120
KW  - Adult
KW  - Aged
KW  - Ambulatory Care
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Blood Sedimentation
KW  - Carcinoma, Renal Cell
KW  - drug therapy
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - France
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Interferon-alpha
KW  - Interleukin-2
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Prognosis
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2003.02.073
ER  -